Call Us Contact Us
+44 1494 818 000     Online Enquiry
Lines open
Monday to Thursday
08:30 to 18:00
Friday
08:30 to 17:30
Pharmaceutical | Medical Devices | Scientific | Consumer Healthcare | Dental | Animal Health
Healthcare Communications | Pharmaceutical Executive | Medical Executive | Tech PR | Scientific Executive
         
Latest Jobs
Exclusive vacancies may not be shown here, please contact Phil on +44 1494 818040 or phil@zenopa.com for more information.
Have you registered?
Once you register you can see additional job details, save jobs, track your applications and manage e-lert preferences.

Register now
Phil Hardy
Senior Account Manager
phil@zenopa.com
+44 1494 818040

Testimonials
Your encouragement and support have been invaluable throughout the process, whether its in calming my increasingly frayed nerves, keeping my constantly up-to-date with developments.
Claire, 2011

Bayer HealthCare reports positive trial data for Xarelto

25 July 2011 00:00 in Pharmaceutical Company Product News


Bayer HealthCare has reported positive data from a new phase III clinical study of Xarelto, in which the drug met its primary endpoint.

The rivaroxaban therapy has been trialled among Japanese patients in a study called J-Rocket AF, which was conducted among patients with non-valvular atrial fibrillation at risk of stroke, in order to evaluate its safety.

When compared to warfarin, it was shown to offer non-inferior performance when assessing composite criteria of major and non-major clinically relevant bleeding.

Dr Masatsugu Hori, steering committee chairman for the latest trial, said: "It is important that rivaroxaban demonstrated non-inferior safety and that there were numerically fewer intracranial haemorrhages versus warfarin."

Thus far, Xarelto has been approved in more than 85 different countries as a means of preventing venous thromboembolism events among adult patients following elective hip or knee replacement surgery.

Earlier this month, Bayer HealthCare announced a new research alliance with the Ludwig Boltzmann Institute for Lung Vascular Research, which will focus on studies into pulmonary hypertension.ADNFCR-8000103-ID-800632368-ADNFCR

Other news stories from 25/07/2011

Related news

Read more in the Zenopa News Archive

How this news is generated

Story collated for Zenopa by the Axonn News Agency



                    
© Copyright 2014 Zenopa Ltd